OBJECTIVE: To evaluate physiologically based pharmacokinetic modelling (PBPK) software in paediatric @entity565 @entity1 using intravenous @entity3416 . METHODS: Prospective clinical audit of @entity1 receiving iv @entity3416 (July 2014 to June 2016), and in-silico modelling using Simcyp software. RESULTS: Thirty-eight admissions (25 @entity1 ) were included. @entity1 with @entity3416 levels >= 10  mg/l had equivalent clinical outcomes compared to those <10  mg/L, and adverse effects occurred in 57%. @entity734 ( @entity734 ) data correlated well with PBPK model. PBPK modelling of a 5  mg/kg iv loading dose (<= 18yr) shows a mean Cmax of 8.99  mg/L (5th-95th centiles 5.5-13.7  mg/L), with 70.3% of subjects <10  mg/L, 29.4% achieving 10-20  mg/L, and 0.1%  >  20  mg/L. For an @entity3416 infusion (0-12  y) of 1.0    mg/kg/h, the mean steady state infusion concentration was 16.4  mg/L, (5th-95th centiles 5.3-32  mg/L), with 26.8% having a serum concentration >20  mg/L. For 12-18yr receiving 0.5    mg/kg/h infusion, the mean steady state infusion concentration was 9.37  mg/L (5th-95th centiles 3.4-18  mg/L), with 59.8% having a serum concentration <10  mg/L. CONCLUSION: PBPK software modelling correlates well with clinical data. Current @entity3416 iv loading dosage recommendations achieve levels <10  mg/l in 70% of @entity1 . Routine @entity734 may need altering as low risk of @entity137 (>20  mg/l).

Using pharmacokinetic modelling to improve prescribing practices of intravenous XXXX in childhood @entity565 exacerbations.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3416 :: ('MESH:D000628', 'Chemical') :: ['aminophylline'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity734 :: ('MESH:D019966', 'Disease') :: ['TDM', 'Therapeutic drug monitoring']
@entity3416 :: (MESH:D000628,Chemical) :: ['aminophylline']
